[Skip to Content]
[Skip to Content Landing]
Citations 0
October 15, 2003

Cost-effectiveness of Treatment for Chronic Hepatitis C Infection

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(15):1993-1994. doi:10.1001/jama.290.15.1993-a

To the Editor: In their cost-effectiveness analysis, Dr Salomon and colleagues1 found that newer treatment options for hepatitis C virus (HCV) infection appear to be reasonably cost-effective. These results, however, varied widely across different patient subgroups and were reflected largely in quality of life rather than increased survival. These conclusions were based on a Markov model in a theoretical cohort of 40-year-old patients with abnormal alanine aminotransferase levels, detectable serum HCV RNA, and a liver biopsy revealing no fibrosis.